There's a prevailing belief from a growing number of posters on this board that the share price has a linear 1:1 relationship with the value of the product (Lenz), which is FAR TOO SIMPLISTIC.
Any time there's a SP rally or crumb of news, people on this board RUSH to:
(1) try and explain the SP climb by inferring there's some clinical or commercialization progress (ie. EUA, enrollment #s, etc) that has yet to be published
or
(2) offer that the news that just broke is going to be the piece of the puzzle that finally helps gain traction for the SP to climb to whatever price target they're eyeing.
... Now, again, for the 100th time, I bought the majority of my shares pre split around between $0.87-$0.95 before averaging up a a little, and I HAVE NOT SOLD OR SHORTED a single share.... I say this to illustrate my confidence in HGEN before continuing to my next point...
the point that i'm trying to make, is that there is a 2nd variable that influences share price fluctuation that isn't being captured with the same veracity as clinical value on this board, and that variable is Market Maker/ Large investor stock price manipulation.
Everyone is trying to explain the day-to-day share price of HGEN with the efficacy of Lenz, or it's viability in the market, or the likelihood of an EUA, and that's too reductionist.
HGEN is undoubtedly going to rocket past $100 in due time, I believed that in June 2020 and have even more conviction for that sentiment today. HOWEVER, I'm getting sick and tired of the mindless circle jerking of people trying to explain the share price solely via clinical value.
People have to understand that UNTIL HGEN crosses the finish line with Lenz (ie. receiving EUA w/ national stockpile POs received etc) there is a 2nd arm that is artificially influencing the share price.
ie. Nomis bay ratcheting up the share price last week and earlier this week to sell shares... that rally was NOT DRIVEN by EUA approval, but rather by Nomis and the partner MM exploiting the potential for EUA.... and the inability for people to grasp or value that concept on here is perplexing.
So, Abaj, to answer your question directly... 1 present reality that the board in general turned a blind eye to was Tuesday's trading.
----
Tue 1/19 - 1:20pm - HGEN @ $20.30 ... Share price drops drastically to 19.62 before creeping back up subtly.
Tue 1/19 - 1:40-2:20pm - high volume trading between $19.71 - $19.99 ... I believed (and still do) that this was the time that Nomis Bay was executing their trades for the day. During the day I told myself "I bet one of Nomis' trades will be listed at $19.80"..... as it turns out, the Form 4 for Nomis' trade that day showed up as $19.81
----
I bring that up because time/sales is realtime tangible evidence that justifies daily price action, especially when it's validated by a Form 4 the same day... but that reality is being overlooked while people like MWM on this board are scouring old Remdesivir clinical trials, or twitter, or Jerry on stocktwits for anecdotal warm fuzzies to reassure themselves.
Again, to the people who think i'm being critical of HGEN, or that i'm a non believer, let me again reassure you that that's not the case... we're all in agreement that HGEN is going to succeed and fly above $100, and I AM AMONGST YOU in that belief... but the urge to try and correlate every day's price action to lenz's clinical and commercial development is juvenile and frankly absurd. there are many factors influencing our price here, i just want that to be recognized so that not every dip/rally triggers some mad dash to find a way to construe clinical reports/updates to justify it. there can be multiple factors influencing price here guys, it's not just just 1 thing despite the singular clinical/commercial development the board seems to be fixated on these days.
AI
